July 16, 2021 10:40 AM EDTUpdated 04:12 PM

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Copy Chief

→ Covid-19 variants have marred the effectiveness of Eli Lilly and AbCellera’s bamlanivimab to such an extent that the US government stopped using the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Copy Chief

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

2024's biopharma winners and losers; CagriSema falls short; Merck swings China GLP-1 deal; and more

Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to rox­adu­s­tat re­buff

Editor

Copy Chief

Sign up to read this article for free.

more like this

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff